Review Article

Inflammatory changes in Covid19 patients and role of tocilizumab

Heba A. Ebrahim[1], Nezar R. Tawfik[1] and Rasha A. Abdelfattah[1]

[1] Department of Chest Diseases, Faculty of Medicine, Minia university

Abstract

COVID-19 is a fast-growing worldwide danger that the WHO has classified as a pandemic. COVID-19 infects the patient's respiratory tract and causes pneumonia in the majority of patients. It can also cause acute respiratory distress or ARDS in roughly 15 percent of Covid-19 cases. The existence of the virus's so-called "cytokine storm" Covid-19 infection was therefore linked to death in patients.. Increased proinflammatory cytokine production exacerbates ARDS and causes significant tissue damage. Due to that fact, there is also the chance that It can cause multi-organ organ failure in certain circumstances. Using cytokines as a target during COVID-19 treatment might help patients live longer and die less. Due to the fact that IL-6 is one of the likely reported cytokines to be enhanced in people who are suffering from Covid-19. Also, it is proven that elevated IL-6 can be directly linked to higher levels of death, tocilizumab is the ideal solution as a therapy for a cytokine storm that can come with Covid-19.

Keywords: COVID-19; tocilizumab; Inflammatory changes

Introduction

The disease which is known as acute respiratory syndrome coronavirus 2 (SARS-CoV-2) plagued many people all over the world since its discovery in December 2019, it has caused the death of hundreds of thousands of people. It also impacted the economy of the whole world causing many countries to be affected. Even though most patients diagnosed with SAR-CoV-2 and developing coronavirus disease 2019 (COVID-19) have minor symptoms, around 14% have severe symptoms, while 5percent of the total have a life-threatening illness, which includes respiratory distress, crisis, and/or multi-organ failure [1].

Lung damage can be the leading cause of mortality after getting the coronavirus [2]. Just like with coronavirus 2 inside the setting of intracellular severe acute respiratory infection (SARS-CoV-2)[3], the autopsy of the lungs revealed considerable alveolar destruction and perivascular T-cell infiltration. This virus is reported to produce immunologic dysfunction after infection by releasing a high number of proinflammatory cytokines, similar to cytokine release syndrome (CRS) [4,5]. Interleukin-6 (IL-6) is assumed to have a major role in the development of acute respiratory distress syndrome (ARDS) among the many cytokines produced [6,7].

The goal of this review is to exhibit the cytokine storm's characteristics in conjunction with COVID-19, as well as to investigate the effect of tocilizumab as an IL6 inhibitor.

Infection with Covid 19 causes a cytokine storm.

A "cytokine storm," which is an activation cascade of auto-amplifying cytokine produc-ction, emerges as a result of an unregulated host immune response to numerous stimuli. Infections, cancer, rheumatic disorders, and other variables all had a role in the development of the disease. A cytokine storm, according to

another researcher An inflammation reaction to an illness is characterised as medications that results in increased immune cell activation and cytokine synthesis[8].

The pathogenesis is complex, but it includes both local and systemic loss of regulatory control over proinflammatory cytokine production. The disease is rapidly advancing, and the mortality rate is high. Certain evidence shows that dysregulated and excessive cytokine release was connected to substantial deterioration in certain patients Was during coronavirus disease epidemic of 2019.

TNF, IL-1, and IL6 are some of the most widely used and significant pro-inflammatory cytokines that can be produced in the human body to serve as an immune response. During that immune response, mast cells, tissue necrophages, epithelial cells, and endothelium can be the primary sources of cytokines [9]. A "cytokine storm" A fast increase in the circulation of many pro-inflammatory cytokines, like the IL-6, IL-1, TNF-, and interferon, causes inflammation. The rise in cytokines produces an inflow of immune cells out from bloodstream into to the site of injection, causing tissue damage via destabilised endothelial cell-cell interactions, vascular barrier injury, capillary damage, widespread alveolar injury, multiorgan failure, and death [10]. The cytokine storm may cause lung damage, leading to acute lung injury or ARDS[11]. ARDS, which is characterised by low oxygen levels, is a significant cause of death in COVID-19. Although the specific cause of ARDS in COVID-19 individuals is unknown, increased pro-inflammatory cytokine production is undoubtedly a component. It will be the topic of mortality and morbidity studies in the future.

Clinical and laboratory problems associated with cytokine storms

During COVID-19, ARDS is a primary cause of death due to low oxygen levels. Although the specific cause of ARDS in COVID-19 sufferers is unknown, increased pro-inflammatory cytokine production is obviously a contributing component. Prospective morbidity and mortality studies will indeed be conducted on it. The development and severity of cytokine storms differ depending on the cause and the

medications used[12]. Almost every cytokine storm patient has a fever, according to [13]. Anorexia, fatigue, headaches, rash, diarrhea, arthralgia, myalgia, and neuropsychiatric problems are all prevalent symptoms. These signs and symptoms might be the result of immune-cell-mediated reactions or tissue damage caused by cytokines or physiological changes in the acute During COVID-19, ARDS is a primary cause of death due to low oxygen levels. Although the specific cause of ARDS in COVID-19 sufferers is unknown, increased pro-inflammatory cytokine production is obviously a contributing component. Prospective morbidity and mortality studies will indeed be conducted on it. Many individuals are experiencing respiratory issues such as coughing or tachypnea. which can escalate to ARDS and hypoxemia, necessitating the need for respiratory support. Individuals with cytokine storms are now at a high risk of spontaneous bleeding due to the combination of hyper inflammation, coagulopathy, and low platelet levels.

Cytokine storms can cause severe symptoms such as renal failure, acute liver injury, or cholestasis[14]. The symptom of neurologic toxicity is encephalopathy.[12] The cytokine storm's neurotoxic effects are usually delayed, arriving many days after the cytokine storm began.

The findings of the cytokine storm study are contradictory. C-reactive protein or CRP is an example of a high-level nonspecific inflammatory marker that corresponds with the severity of the condition. Leukopenia, anemia, thrombocytopenia, as well as elevated ferritin and d-dimer levels, are all symptoms of leukocytosis. The complicated interplay between cytokine-induced changes in bone marrow cell production and mobilization, chemokine-induced migration, and immune-mediated destruction is thought to be the cause of variations in circulating cell numbers. T-cell activation is characterised by the presence of elevated amounts of interferon (or CXCL9 and CXCL10, chemokines generated by interferon), interleukin-6, interleukin-10, and soluble interleukin-2 receptor alpha in the blood. In CAR T-cell therapy–induced cytokine storm and a number of other cytokine storm illnesses, blood interleukin-6 able to contribute positively

[13]. T-cell activation is characterised by the presence of elevated amounts of interferon (or CXCL9 and CXCL10, chemokines generated by interferon), interleukin-6, interleukin-10, and soluble interleukin-2 receptor alpha in the blood. In CAR T-cell therapy–induced cytokine storm and a number of other cytokine storm illnesses, blood interleukin-6 able to contribute positively [13].T-cell activation is characterised by the presence of elevated amounts of interferon (or CXCL9 and CXCL10, chemokines generated by interferon), interleukin-6, interleukin-10, and soluble interleukin-2 receptor alpha in the blood. In CAR T-cell therapy–induced cytokine storm and a number of other cytokine storm illnesses, blood interleukin-6 able to contribute positively [13].

Tocilizumab is indeed a viable therapy for something like the cytokine storm related to COVID-19 since IL-6 is by far the most often reported cytokine to be elevated in COVID-19 patients, and high IL-6 levels have indeed been connected to greater mortality. Tocilizumab was used to treat 21 patients with significant and urgent COVID-19 in China, and the outcomes were encouraging [16].

IL-6 Inhibition and role of Tocilizumab
Tocilizumab (TCZ) is a monoclonal antibody that blocks IL-6 from attaching to its receptor and causing immunosuppression.

TCZ effectively lowered CRP in all 15 patients (n = 15), according to Luo et al.,[17], however, three of them, who was severely unwell, died. Xu et al., Xu et al., Xu et al., [18], Xu et al., Xu et al., Xu et al., Xu et al., Xu et al The effectiveness of TCZ in treating acute COVID-19 symptoms including temperature and respiration have been proven. Every one of the individuals (n = 21, two of whom were seriously sick) recovered and were released from the hospital, with no adverse effects recorded throughout therapy. The preliminary outcomes of off-label therapy of A prospective open-label, multicenter single-arm study of TCZ in severe COVID-19 patients is provided [19]. TCZ enhanced pulmonary and laboratory markers such as Pa02 and Fi02 in 63 people with severe COVID-19, improving their odds of survival (the death rate in the study is 11 percent).

Other lines of treatment include:
(1) Glucocorticoids
Therapeutic glucocorticoids have anti-inflammatory effects both on the innate and adaptive immune response. Because of their extensive anti-inflammatory characteristics, glucocorticoids are a cornerstone of immune-suppressive treatment. Because of their longer plasma half-life, better parenteral absorption, and lesser binding to CBG, synthetic gluco-corticoids like dexamethasone and prednisolone have a higher effectiveness than cortisol. Due to its widespread expression level and large-scale GR-mediated transcriptional alterations – roughly 20% of the genome is susceptible to GR – glucocorticoids are not only strong immunosuppressants but also have extensive off-target effects [20].

* Remdisivir:
One therapy option is redelivering (GS-5734), an adenosine analog that's also incorporated into nascent viral RNA chains and causes them to terminate prematurely[21]. Some other investigational medicine being studied to treat Ebola virus infections is Remdesivir. Remde-sivir, in particular, has shown antiviral effectiveness in animal models of SARS and MERS [22]. In a recent in vitro investigation, the EC90 value of remdesivir vs SARS-CoV-2 in Vero E6 cells was 1.76 M, The influential concentration seems likely to be achieved in vivo, according to the findings. Therapeutic remdesivir therapy has been demonstrated to lower viral load in SARS-CoV-2-infected rhesus macaques when administered early [23].

*Chloroquine and hydroxychloroquine are two types of chloroquine
Antiviral effects of CQ and HCQ have indeed been demonstrated against a range of viruses. include dengue, chikungunya, and Ebola. Any influence identified so far has been limited to in vitro cultivation. In vivo efficacy has not been demonstrated. Several randomized controlled studies are being carried out to see if CQ and HCQ are effective in treating or even preve-nting COVID-19. HCQ was reported to be effective against SARS-CoV-2 in a recent French investigation, especially when paired with azithromycin[24]. The tiny sample sizes employed in every study hampered the experts' recommendations.

*Lopinavir\ritonavir:
To treat HIV-1 infection, the protease inhibitors lopinavir/ritonavir (LPV/r) are used. HAART (highly active antiretroviral treatment) is another name for it (HAART). In SARS patients, a combination of LPV/r plus extra ribavirin has indeed been demonstrated to decrease the occurrence or mortality of acute respiratory distress syndrome [25]. LPV/r with interferon have been shown to be more effective than controls in treating MERS-CoV illness in animal studies and case studies. Because SARS-CoV-2 is genetically identical to MERS-CoV and SARS-CoV, LPV/r was adapted for treating COVID-19.

* Ivermectin:
Despite it having only been investigated in vitro, recent research on the FDA-approved anti-parasitic medicine ivermectin appears to be especially effective [27]. An emergency clinical study to repurpose such approved drugs is necessary.

* Plasma from patients in remission:
COVID-19 treatment combined with convalescent plasma could be a viable option. The medical state of all five severely sick COVID-19 patients receiving convalescent plasma improved significantly. within one week before the infusion, notably normalizing of body temperature and scores on the sequential organ failure evaluation, according to a new case study. Furthermore, the patients' neutral-lizing antibody titers improved 1–12 days after the injections, and respiratory specimens were negative against SARS-CoV-2[28]. The viral blood work in seven persons who had already experienced significant viremia in that other investigation of ten severe cases were undetectable after the injections [29].

Conclusion
We have sought to summarize virology and related pathophysiology in this study, with a focus on immunopathology. SARS-CoV-2 infecting lung epithelial cells and possibly particular immune cells immediately via infectious aerosolized droplets heralds the illness. TNF- and IL-6 have been identified as potential illness severity markers.

Furthermore, the patients' neutralizing antibody titers improved 1–12 days after the injection, and SARS-CoV-2 respiratory samples were negative [28]. After the treatment, the virus titers in 7 people who previously experienced considerable viremia became insignificant in another study of 10 serious conditions [29].

Tocilizumab is indeed a contender since IL-6 is by far the most often documented cytokine to also be raised in COVID-19 victims, and greater IL-6 concentrations have indeed been associated with higher death rates. Tocilizumab proven to be a suitable therapy for suffering from of the cytokine storm linked to COVID-19, as IL-6 is the most often documented cytokine to be raised in COVID-19 cases, and greater IL-6 concentrations have been associated with increased mortality.

References
1. Efficacy and safety of tocilizumab in COVID-19 patients: a living systematic review and meta analysis. Rana Tleyjeh, Leslie Hassett, Tarek Kashour. November 05,2020.CMI Clinical Microbiology and Infection).
2. Chen N, Zhou M, Dong X, Qu J, Gong F, Han Y, Qiu Y, Wang J, Liu Y, Wei Y, Xia J, Yu T, Zhang X, Zhang L. Epidemiological and clinical character-ristics of 99 cases of 2019 novel corona-virus pneumonia in Wuhan, China: a descriptive study. Lancet. 2020; 395 (10223):507–13.
3. Ackermann M, Verleden SE, Kuehnel M, Haverich A, Welte T, Laenger F, Vanstapel A, Werlein C, Stark H, Tzankov A, Li WW, Li VW, Mentzer SJ, Jonigk D. Pulmonary vascular endothelialitis, throm-bosis, and angiogenesis in Covid-19. N Engl J Med. 2020;383:1208. https://doi.org/10.1056/NEJMoa2015432.
4. Brune K, Frank J, Schwingshackl A, Finigan J, Sidhaye VK. Pulmonary epi-thelial barrier function: some new players and mecha-nisms. Am J Physiol Lung Cell Mol Physiol. 2015;308(8): L731–45.
5. Siddiqi HK, Mehra MR. COVID-19 illness in native and immunosuppressed states: a clinical-therapeutic staging proposal. J Heart Lung Transplant. 2020;39(5):405–7
6. Zhang C, Wu Z, Li J, Zhao H, Wang G. Cytokine release syndrome in severe

COVID-19: interleukin-6 receptor antago-nist tocilizumab may be the key to reduce the mortality. Int J Antimicrob Agents. 2020;55(5):105954.

7. Coomes EA and Haghbayan H. Interleukin-6 in COVID-19: A systematic review and meta-analysis. medRxiv 2020. https://doi. org/10.1101/2020.03.30.20048058. (pre-print).

8. cytokines 2. Tisoncik JR, Korth MJ, Simmons CP, Farrar J, Martin TR, Katze MG. Into the eye of the cytokine storm. Microbiol Mol Biol Rev. 2012;76:16–32.

9. Chen, N., et al., Epidemiological and clinical characteristics of 99 cases of 2019 novel coronavirus pneumonia in Wuhan, China: a descriptive study. The lancet, 2020. 395(10223): p. 507-513.

10. Kalaiyarasu, S., et al., Highly pathogenic avian influenza H5N1 virus induces cytokine dysregulation with suppressed maturation of chicken monocyte-derived dendritic cells. Microbiology and immune-logy, 2016. 60(10): p. 687-693.

11. Shimizu, M., Clinical features of cytokine storm syndrome, in Cytokine storm syndrome. 2019, Springer. p. 31-41.

12. Lee DW, Santomasso BD, Locke FL, et al., ASTCT consensus grading for cytokine release syndrome and neurologic toxicity associated with immune effector cells. Biol Blood Marrow Transplant2019;25:625-638

13. Grupp SA, Kalos M, Barrett D, et al., Chimeric antigen receptor-modified T cells for acute lymphoid leukemia. N Engl J Med 2013;368:1509-1518.

14. Templin C, Ghadri JR, Diekmann J, et al., Clinical features and outcomes of takotsubo (stress) cardiomyopathy. N Engl J Med 2015;373:929-938.

15. Lee DW, Gardner R, Porter DL, et al., Current concepts in the diagnosis and management of cytokine release syndrome. Blood 2014;124:188-195.

16. Organization, W.H., Novel Coronavirus (2019-nCoV): situation report, 11. 2020.

17. Luo P, Liu Y, Qiu L, Liu X, Liu D, Li J. Tocilizumab treatment in COVID-19: a single center experience. J Med Virol. (2020) 92:814–8. 10.1002/jmv.25801

18. Xu X, Han M, Li T, Sun W, Wang D, Fu B, et al., Effective treatment of severe COVID-19 patients with tocilizumab. Proc Natl Acad Sci USA. (2020) 117:10970–5.

19. Sciascia S, Apra F, Baffa A, Baldovino S, Boaro D, Boero R, et al., Pilot prospective open, single-arm multicentre study on off-label use of tocilizumab in severe patients with COVID-19. Clin Exp Rheumatol. (2020) 38:529–32.

20. Galon, J., et al., Gene profiling reveals unknown enhancing and suppressive actions of glucocorticoids on immune cells.The FASEB journal,2002.16(1):p.61-71.

21. Warren, T.K., et al., Therapeutic efficacy of the small molecule GS-5734 against Ebola virus in rhesus monkeys. Nature, 2016. 531(7594): p. 381-385.

22. de Wit, E., et al., Prophylactic and therapeutic remdesivir (GS-5734) treatent in the rhesus macaque model of MERS-CoV infection. Proceedings of the National Academy of Sciences, 2020. 117(12): p. 6771-6776.

23. Williamson, B.N., et al., Clinical benefit of remdesivir in rhesus macaques infected with SARS-CoV-2. Nature, 2020. 585 (7824): p. 273-276

24. Sahraei, Z., et al., Aminoquinolines against coronavirus disease 2019 (COVID-19): chloroquine or hydroxychloroquine. Int J Antimicrob Agents,2020. 55(4): p. 105945.

25. Chan, K., et al., Treatment of severe acute respiratory syndrome with lopinavir/ ritonavir: a multicentre retrospective matched cohort study. Hong Kong medical journal, 2003.

26. Kim, U.J., et al., Case report Combination therapy with lopinavir/ritonavir, ribavirin and interferon-α for Middle East respire-atory syndrome. Antiviral therapy, 2016. 21: p. 455-9.

27. Caly, L., et al., The FDA-approved drug ivermectin inhibits the replication of SARS-CoV-2 in vitro. Antiviral research, 2020. 178: p. 104787.

28. Shen, C., et al., Treatment of 5 critically ill patients with COVID-19 with convalescent plasma. Jama, 2020.323(16): p. 1582-1589.

29. Duan, K., et al., Effectiveness of convales-cent plasma therapy in severe COVID-19 patients. Proceedings of the National Academy of Sciences, 2020. 117(17): p. 9490-9496.